Company profile
NervGen Pharma Corp. Common stock
NASDAQ: NGEN · Healthcare · Biotechnology
Canadian filerHQ West Vancouver, BCCIK 0001751912Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 27DQ —GM —SS 38
v0.1 · 35/100 weight · pillars only
↑ market scale, Altman-Z · ↓ return on equity, filing timeliness
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$31.6M
Employees
8
as of 2026-08-14
Market cap
$144.7M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$31.6M-44.1M CAD2025
Total assets$16.9M23.2M CAD2025
Liabilities$14.4M19.7M CAD2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is NervGen Pharma Corp. Common stock’s financial profile?
NervGen Pharma Corp. Common stock earned -$31.6M in FY2025 net income.
Peers · Healthcare
Armata Pharmaceuticals, Inc.——Canton Strategic Holdings Inc——Indaptus Therapeutics, Inc.——Milestone Pharmaceuticals Inc.——Polaryx Therapeutics, Inc. Common Stock——Nautilus Biotechnolgy, Inc.——Key facts
CEOAdam H. Rogers
SectorHealthcare
IndustryBiotechnology
HeadquartersWest Vancouver, BC
ExchangeNASDAQ: NGEN
Employees8
IPO date2021-02-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.